On May 26, 2021 Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, reported the filing of a provisional composition of matter patent titled "Urokinase Plasminogen Activator Receptor-Targeted Radiopharmaceutical" covering a radiotherapeutic consisting of Monopar’s proprietary antibody MNPR-101 bound to Actinium-225 (Ac-225) via the metal binding agent PCTA (Press release, Monopar Therapeutics, MAY 26, 2021, View Source [SID1234580632]). This Radio-Immuno-Therapeutic (RIT) demonstrated a 98% radiochemical purity and has the potential to be a highly selective, potent treatment for a variety of cancers, severe COVID-19, and other diseases characterized by aberrant urokinase plasminogen activator receptor (uPAR) expression.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

RITs are an emerging class of drugs formed by attaching a radioactive element to an antibody for the purpose of targeting and killing specific cells. Actinium is quickly becoming a premier radioisotope of choice for RITs; however, its full potential is presently constrained by its price and scarcity. On May 24, 2021, Monopar and NorthStar announced the filing of a provisional patent which may enable them to manufacture antibody-PCTA-Ac225 conjugates using less antibody and less Ac-225 starting material, and may also confer efficacy and safety advantages while also improving supply chain logistics.

"We are excited about working with Monopar to develop MNPR-101 as a radio-immuno-therapeutic, and advancing it further toward the clinic," said James Harvey, PhD, Chief Scientific Officer of NorthStar.

"The binding of Actinium-225 to PCTA-MNPR-101 with 98% yield is highly encouraging," said Andrew Mazar, PhD, Monopar’s Chief Scientific Officer. "If issued, this composition of matter patent could significantly expand the MNPR-101 patent estate."

On May 26, 2021 Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, reported that management will present a corporate overview at the Jefferies Virtual Healthcare Conference on Friday, June 4, 2021 at 8:30am EST (Press release, Purple Biotech, MAY 26, 2021, globenewswire.com/news-release/2021/05/26/2236298/0/en/Purple-Biotech-to-Present-at-the-Jefferies-Virtual-Healthcare-Conference.html [SID1234580631]). The conference will take place from June 1 – June 4, 2021. Management will be available for one-on-one meetings.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies Virtual Healthcare Conference – June 1-4, 2021

Date: Friday, June 4, 2021

Time: 8:30-8:55am EST

Webcast: Virtual webinar link here

Webcast Replay Link: A replay will be accessible on the Events & Presentations page of the Investors section on the Company’s website at View Source

On May 26, 2021 iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, reported that Michel Detheux, PhD, President and Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 8:00 a.m. ET (Press release, iTeos Therapeutics, MAY 26, 2021, View Source [SID1234580630]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on the Investors section of the company’s website at View Source An archived replay will be available for approximately 30 days following the presentation.

On May 26, 2021 Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, reported that the Company will present at the upcoming Jefferies Virtual Healthcare Conference taking place June 1-4, 2021 (Press release, Zymeworks, MAY 26, 2021, View Source [SID1234580626]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company’s presentation will be on Thursday, June 3, 2021 at 10:00 a.m. ET.

Interested parties can access a live webcast of the presentation via a link from Zymeworks’ website at View Source, which will also host a recorded replay available afterwards.

On May 26, 2021 Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, reported that the Company will present at the upcoming Jefferies Virtual Healthcare Conference taking place June 1-4, 2021 (Press release, Zymeworks, MAY 26, 2021, View Source [SID1234580625]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company’s presentation will be on Thursday, June 3, 2021 at 10:00 a.m. ET.

Interested parties can access a live webcast of the presentation via a link from Zymeworks’ website at View Source, which will also host a recorded replay available afterwards.